» Articles » PMID: 31911433

Cracking the Context-specific PI3K Signaling Code

Overview
Journal Sci Signal
Date 2020 Jan 9
PMID 31911433
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Specificity in signal transduction is determined by the ability of cells to "encode" and subsequently "decode" different environmental signals. Akin to computer software, this "signaling code" governs context-dependent execution of cellular programs through modulation of signaling dynamics and can be corrupted by disease-causing mutations. Class IA phosphoinositide 3-kinase (PI3K) signaling is critical for normal growth and development and is dysregulated in human disorders such as benign overgrowth syndromes, cancer, primary immune deficiency, and metabolic syndrome. Despite decades of PI3K research, understanding of context-dependent regulation of the PI3K pathway and of the underlying signaling code remains rudimentary. Here, we review current knowledge on context-specific PI3K signaling and how technological advances now make it possible to move from a qualitative to quantitative understanding of this pathway. Insight into how cellular PI3K signaling is encoded or decoded may open new avenues for rational pharmacological targeting of PI3K-associated diseases. The principles of PI3K context-dependent signal encoding and decoding described here are likely applicable to most, if not all, major cell signaling pathways.

Citing Articles

Phenotypic consequences of logarithmic signaling in MAPK stress response.

Jashnsaz H, Neuert G iScience. 2025; 28(1):111625.

PMID: 39886462 PMC: 11780147. DOI: 10.1016/j.isci.2024.111625.


PIK3CA mutation fortifies molecular determinants for immune signaling in vascular cancers.

Lee D, Kozurek E, Abdullah M, Wong E, Li R, Liu Z Cancer Gene Ther. 2024; 32(2):254-267.

PMID: 39709507 PMC: 11839470. DOI: 10.1038/s41417-024-00867-4.


Oncogenic PIK3CA corrupts growth factor signaling specificity.

Madsen R, Le Marois A, Mruk O, Voliotis M, Yin S, Sufi J Mol Syst Biol. 2024; 21(2):126-157.

PMID: 39706867 PMC: 11791070. DOI: 10.1038/s44320-024-00078-x.


When, where and which PIK3CA mutations are pathogenic in congenital disorders.

Angulo-Urarte A, Graupera M Nat Cardiovasc Res. 2024; 1(8):700-714.

PMID: 39196083 DOI: 10.1038/s44161-022-00107-8.


Selective PI3Kδ inhibitor TYM-3-98 suppresses AKT/mTOR/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer.

Zheng Y, Lou S, Lu J, Zheng F, Tang Y, Zhang E Cell Death Dis. 2024; 15(7):474.

PMID: 38956060 PMC: 11220027. DOI: 10.1038/s41419-024-06848-7.